8-K: FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

FibroGen announces Q1 2025 financial results, an update on the sale of FibroGen China to AstraZeneca, and progress on its drug development programs.

Summary

• FibroGen reported its first quarter 2025 financial results on May 12, 2025.
• Total revenue from continuing operations was $2.7 million, compared to $25.4 million in the first quarter of 2024.
• Net loss from continuing operations was $16.8 million, or $0.16 per share, compared to a net loss of $49.0 million, or $0.49 per share, in the same period last year.
• The sale of FibroGen China to AstraZeneca is now expected to result in total consideration of approximately $185 million, a $25 million increase from initial guidance.
• Net cash held in China at closing is estimated to be approximately $100 million.
• The transaction is expected to close in the third quarter of 2025.
• Upon closing of the sale, FibroGen expects its cash runway to extend into the second half of 2027.
• The company anticipates initiating a Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in the third quarter of 2025.
• Topline results from the Phase 2 portion of an investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC are expected in the fourth quarter of 2025.
• FibroGen has filed a Type-C meeting request with the FDA for roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) and expects feedback in the third quarter of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While revenue is down, the increased consideration for the FibroGen China sale, extended cash runway, and progress in clinical trials contribute to a positive outlook.

Positives

• The sale of FibroGen China to AstraZeneca is expected to generate approximately $185 million in total consideration, $25 million more than previously expected.
• FibroGen's cash runway is expected to extend into the second half of 2027 following the sale of FibroGen China.
• The company is advancing its lead asset, FG-3246, with the expected initiation of a Phase 2 monotherapy trial in mCRPC in Q3 2025.
• FibroGen maintains its rights to roxadustat in the U.S. and in all markets outside of China, South Korea, and those licensed to Astellas.
• Net loss decreased from $49.0 million to $16.8 million year over year.

Negatives

• Total revenue from continuing operations decreased significantly from $25.4 million in Q1 2024 to $2.7 million in Q1 2025.

Risks

• The closing of the sale of FibroGen China is subject to customary closing conditions and may not occur as expected.
• The development of FG-3246 and roxadustat are subject to regulatory risks and may not receive regulatory approval.
• Clinical trial results may not be favorable.
• The company's financial performance is dependent on the successful development and commercialization of its products.

Future Outlook

FibroGen expects its cash, cash equivalents, and accounts receivable to be sufficient to fund operating plans into the second half of 2027 upon closing of the sale of FibroGen China.

Management Comments

• We continue to focus on our most important strategic priority of advancing our lead asset, FG-3246, with the initiation of the Phase 2 monotherapy dose optimization study in mCRPC, expected to start in the third quarter of 2025, said Thane Wettig, Chief Executive Officer, FibroGen.
• As we look to finalize the sale of FibroGen China in the third quarter of 2025, we remain highly focused on driving significant shareholder value by supporting our US development initiatives with our strong balance sheet and extended cash runway into the second half of 2027.

Industry Context

FibroGen is focused on developing novel therapies in cancer biology and anemia, with FG-3246 targeting CD46 in prostate cancer and roxadustat for anemia treatment. The company's activities align with the broader industry trend of developing targeted therapies and addressing unmet medical needs in oncology and hematology.

Comparison to Industry Standards

• FG-3246, as an antibody-drug conjugate (ADC) targeting CD46, is part of a growing class of targeted cancer therapies.
• Companies like Seagen and ImmunoGen have pioneered ADC technology, and FibroGen's approach is similar in that it aims to deliver a cytotoxic payload directly to cancer cells.
• Roxadustat, a HIF-PH inhibitor, competes with other anemia treatments, including erythropoiesis-stimulating agents (ESAs) like Amgen's Epogen and Aranesp.
• However, roxadustat offers a different mechanism of action and is approved in multiple countries, providing a competitive advantage.

Stakeholder Impact

• Shareholders may benefit from the increased consideration from the sale of FibroGen China and the extended cash runway.
• Patients with mCRPC may benefit from the development of FG-3246.
• Patients with anemia associated with LR-MDS may benefit from the potential development of roxadustat for this indication.

Next Steps

• Initiate Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in the third quarter of 2025.
• Obtain FDA feedback on roxadustat in anemia associated with LR-MDS in the third quarter of 2025.
• Receive topline results from the Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC in the fourth quarter of 2025.
• Close the sale of FibroGen China to AstraZeneca in the third quarter of 2025.

Key Dates

Keywords

FibroGen, FG-3246, Roxadustat, AstraZeneca, Financial Results, mCRPC, LR-MDS, Phase 2 Trial, FDA, Sale of FibroGen China, Antibody-Drug Conjugate, Anemia